Form 6-K GSK plc For: Jul 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
GSK halts camlipixant development for chronic cough after mixed results
July 17, 2026 6:55 AM EDTGSK plc (NYSE: GSK) announced it will not advance camlipixant, a P2X3 receptor antagonist, for the treatment of refractory chronic cough (RCC) after mixed results from two phase III clinical trials.
The CALM-1 trial met its primary endpoint, showing statistically significant reductions in 24-hour cough... More
